[go: up one dir, main page]

WO2001066745A3 - Polypeptides de liaison de la preseniline/crk (pcbp) et procedes d'utilisation de ceux-ci - Google Patents

Polypeptides de liaison de la preseniline/crk (pcbp) et procedes d'utilisation de ceux-ci Download PDF

Info

Publication number
WO2001066745A3
WO2001066745A3 PCT/US2001/007024 US0107024W WO0166745A3 WO 2001066745 A3 WO2001066745 A3 WO 2001066745A3 US 0107024 W US0107024 W US 0107024W WO 0166745 A3 WO0166745 A3 WO 0166745A3
Authority
WO
WIPO (PCT)
Prior art keywords
presenilin
crk
crk binding
binding polypeptides
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/007024
Other languages
English (en)
Other versions
WO2001066745A2 (fr
Inventor
David R Schubert
Atsushi Kashiwa
Hideo Kimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salk Institute for Biological Studies
Original Assignee
Salk Institute for Biological Studies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Institute for Biological Studies filed Critical Salk Institute for Biological Studies
Priority to AU2001243425A priority Critical patent/AU2001243425A1/en
Publication of WO2001066745A2 publication Critical patent/WO2001066745A2/fr
Publication of WO2001066745A3 publication Critical patent/WO2001066745A3/fr
Priority to US10/234,961 priority patent/US20030077740A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des polypeptides de liaison de la préséniline/Crk caractérisés par leur interaction avec les polypeptides de la préséniline, leur modulation de la mobilisation de calcium intracellulaire et leur redistribution du cytoplasme à la membrane, en présence d'un polypeptide de la préséniline. Les polypeptides de liaison de la préséniline/Crk sont également caractérisés par leur interaction avec un polypeptide Crk et par la présence d'au moins un domaine SH3 en eux. L'invention concerne également des acides nucléiques isolés codant les polypeptides de liaison de la préséniline/Crk, des anticorps qui se lient aux polypeptides de liaison de la préséniline/Crk, des vecteurs d'expression contenant des polynucléotides de liaison de la préséniline/Crk et des cellules hôtes transformées en polynucléotides de liaison de la préséniline/Crk. L'invention concerne aussi un procédé d'identification d'un composant modulant la mobilisation de calcium intracellulaire et/ou modulant les niveaux ou l'activité de la protéine de liaison de la préséniline/Crk. La présente invention propose également un procédé de traitement d'un trouble associé à la protéine de liaison de la préséniline/Crk. L'invention offre encore un procédé de diagnostic d'un sujet atteint, ou présentant le risque d'être atteint, d'un trouble du système nerveux tel que la maladie d'Alzheimer.
PCT/US2001/007024 2000-03-03 2001-03-05 Polypeptides de liaison de la preseniline/crk (pcbp) et procedes d'utilisation de ceux-ci Ceased WO2001066745A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001243425A AU2001243425A1 (en) 2000-03-03 2001-03-05 Presenilin/crk binding polypeptides (pcbp) and methods of use thereof
US10/234,961 US20030077740A1 (en) 2001-03-05 2002-09-03 Presenilin/Crk binding polypeptides (PCBP) and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51848300A 2000-03-03 2000-03-03
US09/518,483 2000-03-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/234,961 Continuation US20030077740A1 (en) 2001-03-05 2002-09-03 Presenilin/Crk binding polypeptides (PCBP) and methods of use thereof

Publications (2)

Publication Number Publication Date
WO2001066745A2 WO2001066745A2 (fr) 2001-09-13
WO2001066745A3 true WO2001066745A3 (fr) 2002-07-11

Family

ID=24064117

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/007024 Ceased WO2001066745A2 (fr) 2000-03-03 2001-03-05 Polypeptides de liaison de la preseniline/crk (pcbp) et procedes d'utilisation de ceux-ci

Country Status (2)

Country Link
AU (1) AU2001243425A1 (fr)
WO (1) WO2001066745A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1239051A3 (fr) * 2001-01-30 2004-03-17 Aeomica, Inc. Protéine humaine de typ POSH
CA2458207A1 (fr) * 2001-05-03 2002-11-14 Murdoch Childrens Research Institute Determination d'une predisposition genetique a des troubles comportementaux

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046678A1 (fr) * 1996-06-06 1997-12-11 Bayer Corporation Acides nucleiques et polypeptides apparentes a la preseniline
WO1999016874A1 (fr) * 1997-10-01 1999-04-08 Aventis Pharma S.A. Acides nucleiques codant pour des proteines capables d'interagir avec les presenilines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046678A1 (fr) * 1996-06-06 1997-12-11 Bayer Corporation Acides nucleiques et polypeptides apparentes a la preseniline
WO1999016874A1 (fr) * 1997-10-01 1999-04-08 Aventis Pharma S.A. Acides nucleiques codant pour des proteines capables d'interagir avec les presenilines

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BUXBAUM JOSEPH D ET AL: "Calsenilin: A calcium-binding protein that interacts with the presenilins and regulates the levels of a presenilin fragment.", NATURE MEDICINE, vol. 4, no. 10, October 1998 (1998-10-01), pages 1177 - 1181, XP002187372, ISSN: 1078-8956 *
DATABASE EMBL 2 March 2000 (2000-03-02), BONALDO M ET AL: "Normalization and substraction: two appoaches to facilitate gene discovery", XP002187375 *
DATABASE SWISSPROT 1 January 1998 (1998-01-01), NAGASE ET AL: "Prediction of the coding sequences of unidentified human genes.", XP002187374 *
DNA RESEARCH, vol. 4, 1997, pages 141 - 150 *
GENOME RESEARCH, vol. 6, no. 9, 1996, pages 791 - 806 *
HASEGAWA HIDEKI ET AL: "DOCK180, a major CRK-binding protein, alters cell morphology upon translocation to the cell membrane.", MOLECULAR AND CELLULAR BIOLOGY, vol. 16, no. 4, 1996, pages 1770 - 1776, XP002187373, ISSN: 0270-7306 *

Also Published As

Publication number Publication date
WO2001066745A2 (fr) 2001-09-13
AU2001243425A1 (en) 2001-09-17

Similar Documents

Publication Publication Date Title
NZ323795A (en) Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides
IL180967A0 (en) Human toll homologues
WO2001055307A3 (fr) Acides nucleiques, proteines et anticorps
WO1998012328A3 (fr) Polypeptides de bad humaine codant des acides nucleiques et leurs procedes d'utilisation
EP1517144A3 (fr) Procédé d'identification d'anticorps se liant au récepteur vanilloide humain et modifiant l'activité de ce dernier
CA2173102A1 (fr) Sequence d'adn codant pour un recepteur de la proteine morphogenetique osseuse
WO1996031603A3 (fr) Procedes et compositions pour reguler le niveau de la proteine 'fadd'
WO2001005970A3 (fr) Proteines associees de liaison gtp
WO1999024587A3 (fr) Proteine de type phospholipase a2 d'origine humaine et adn la codant
WO2000077239A3 (fr) Nouveaux genes codant pour des proteines a des fins de diagnostic, de prevention, de therapie et autres
WO1999033981A3 (fr) Proteines contenant des sequences-signaux humaines
WO1999033870A3 (fr) Proteines humaines regulatrices
EP0921194A3 (fr) TRAILLK-2: membre de la famille des ligand du TNF
WO1998025956A3 (fr) Nouvelles proteines humaines se liant a la guanosine triphosphate
WO2001016317A3 (fr) Molecules induites par un hydrocarbure aromatique polycyclique
EP0919620A3 (fr) TRAILLK-3: Membre de la famille des ligands du TNF
WO2001066745A3 (fr) Polypeptides de liaison de la preseniline/crk (pcbp) et procedes d'utilisation de ceux-ci
WO1999031128A3 (fr) Proteines du type facteur humain de necrose tumorale r2
DE69831141D1 (de) Z2-19a, ein menschliches homolog von dem protein 2-19
PL324518A1 (en) Polypeptide showing affinity to enamel matrix
WO2000059942A3 (fr) COMPOSITIONS hOB-BP2h, LEURS TECHNIQUES ET LEURS UTILISATIONS
WO2001000638A3 (fr) Nouveaux genes codant des proteines pouvant etre utilisees dans des domaines diagnostiques, preventifs, therapeutiques ou autres
WO1998002557A3 (fr) Fnt-alpha convertase mammalienne
WO2001067097A3 (fr) Nouveau procede d'analyse biologique
WO2000023466A3 (fr) Proteines humaines de fixation de l'arn

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10234961

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP